Brookstone Capital Management Buys 6,687 Shares of Becton, Dickinson and Company (NYSE:BDX)

Posted by on Mar 19th, 2023

Brookstone Capital Management raised its stake in Becton, Dickinson and Company (NYSE:BDX – Get Rating) by 67.3% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 16,623 shares of the medical instruments supplier’s stock after purchasing an additional 6,687 shares during the quarter. Brookstone Capital Management’s holdings in Becton, Dickinson and were worth $4,311,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BDX. Fairfield Bush & CO. bought a new stake in Becton, Dickinson and in the first quarter valued at approximately $114,000. Sequoia Financial Advisors LLC lifted its position in Becton, Dickinson and by 11.3% in the first quarter. Sequoia Financial Advisors LLC now owns 2,923 shares of the medical instruments supplier’s stock valued at $778,000 after purchasing an additional 297 shares during the last quarter. Brighton Jones LLC lifted its position in Becton, Dickinson and by 8.8% in the first quarter. Brighton Jones LLC now owns 1,383 shares of the medical instruments supplier’s stock valued at $368,000 after purchasing an additional 112 shares during the last quarter. Zions Bancorporation N.A. lifted its position in Becton, Dickinson and by 13.0% in the first quarter. Zions Bancorporation N.A. now owns 504 shares of the medical instruments supplier’s stock valued at $134,000 after purchasing an additional 58 shares during the last quarter. Finally, Mather Group LLC. lifted its position in Becton, Dickinson and by 26.0% in the first quarter. Mather Group LLC. now owns 1,346 shares of the medical instruments supplier’s stock valued at $358,000 after purchasing an additional 278 shares during the last quarter. Institutional investors own 87.08% of the company’s stock.

Insider Transactions at Becton, Dickinson and

In other news, EVP Richard Byrd sold 1,421 shares of the stock in a transaction on Friday, February 3rd. The stock was sold at an average price of $248.60, for a total value of $353,260.60. Following the sale, the executive vice president now directly owns 4,119 shares of the company’s stock, valued at $1,023,983.40. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on BDX shares. Morgan Stanley upped their target price on Becton, Dickinson and from $290.00 to $295.00 and gave the company an “overweight” rating in a report on Friday, February 3rd. Piper Sandler upped their target price on Becton, Dickinson and from $245.00 to $260.00 and gave the company a “neutral” rating in a report on Thursday, February 2nd. The Goldman Sachs Group decreased their target price on Becton, Dickinson and from $319.00 to $272.00 and set a “buy” rating for the company in a report on Wednesday, November 23rd. StockNews.com started coverage on Becton, Dickinson and in a report on Thursday. They set a “buy” rating for the company. Finally, Bank of America upgraded Becton, Dickinson and from a “neutral” rating to a “buy” rating and upped their target price for the company from $250.00 to $290.00 in a report on Tuesday, January 3rd. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $271.89.

Becton, Dickinson and Price Performance

BDX opened at $235.58 on Friday. The stock has a fifty day simple moving average of $244.55 and a two-hundred day simple moving average of $241.65. The company has a current ratio of 1.07, a quick ratio of 0.60 and a debt-to-equity ratio of 0.56. The company has a market cap of $66.88 billion, a price-to-earnings ratio of 44.45, a price-to-earnings-growth ratio of 2.48 and a beta of 0.53. Becton, Dickinson and Company has a 12-month low of $215.90 and a 12-month high of $277.29.

Becton, Dickinson and (NYSE:BDX – Get Rating) last posted its quarterly earnings data on Thursday, February 2nd. The medical instruments supplier reported $2.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.68 by $0.30. The business had revenue of $4.59 billion during the quarter, compared to the consensus estimate of $4.59 billion. Becton, Dickinson and had a return on equity of 13.52% and a net margin of 8.47%. The firm’s quarterly revenue was down 2.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.64 earnings per share. Research analysts predict that Becton, Dickinson and Company will post 12.19 earnings per share for the current fiscal year.

Becton, Dickinson and Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, March 31st. Stockholders of record on Friday, March 10th will be paid a $0.91 dividend. The ex-dividend date is Thursday, March 9th. This represents a $3.64 dividend on an annualized basis and a dividend yield of 1.55%. Becton, Dickinson and’s dividend payout ratio is currently 68.68%.

Becton, Dickinson and Company Profile

(Get Rating)

Becton, Dickinson & Co engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery.

Featured Articles

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Get Rating).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.